Vice President of Marketing

Cabaletta Bio Inc.•Philadelphia, PA

1d•Hybrid

About The Position

Cabaletta Bio is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases. The CABA™ platform encompasses two complementary strategies which aim to advance the discovery and development of engineered T cell therapies with the potential to become deep and durable, perhaps curative, treatments for a broad range of autoimmune diseases. The lead CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) strategy is prioritizing the development of rese-cel, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy. Rese-cel is currently being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. At Cabaletta, we are driven by the shared mission of developing cures, where a patients’ own cells are used to fight disease. We are building a culture grounded in the knowledge that successful cures can be achieved for patients if every member of the Cabaletta is focused on the success of the team. To nurture this, we make an active commitment to the well-being and continuous growth of each employee who joins the team. In this way, we are not only working to improve the lives of patients, but of everyone involved. #CabalettaCrew. We’re proud to be a Great Place to Work-Certified™ company! #GPTWcertified A Vice President (VP) of Marketing at Cabaletta Bio develops and executes the commercial marketing strategy to transition the company from a clinical-stage biotechnology firm to a commercial leader in autoimmune cell therapies. Reporting directly to the Chief Commercial Officer (CCO). Create pre-launch and launch strategies for Cabaletta’s lead CAR-T (Chimeric Antigen Receptor T cells for Autoimmunity) candidate, rese-cel (resecabtagene autoleucel), as it heads toward a targeted 2027 FDA filing for myositis, alongside a broader clinical portfolio spanning lupus, systemic sclerosis, and myasthenia gravis.

Requirements

Bachelor’s degree in business, marketing, or life sciences is required
15+ years of progressive commercial marketing leadership in the biopharmaceutical industry, with a proven track record at the Executive Director or VP level.
Hands-on experience with commercializing cell and gene therapies (e.g., CAR-T), orphan drugs, or highly complex specialty therapeutics with intricate hospital treatment logistics is highly critical.
Demonstrated experience working in lean, fast-paced, clinical-to-commercial stage environments where individuals must design long-term strategy while remaining execution-oriented.

Nice To Haves

an MBA or advanced scientific degree (Ph.D., MD, PharmD) is preferred.
Specific marketing background in rheumatology, neurology, or dermatology spaces is highly desirable.

Responsibilities

Architect and execute US commercial launch plans for rese-cel across multiple targeted autoimmune indications, preparing the market for the paradigm shift of CAR-T outside of oncology.
Define clinical branding, scientific narrative, and messaging frameworks that educate stakeholders on the "immune system reset" concept of autologous cell therapy without long-term immunosuppression.
Recruits, structures, and leads a high-performing commercial marketing team across healthcare professional (HCP) marketing, patient advocacy, digital strategy, and consumer awareness.
Partner closely with New Product Planning, Market Access, Medical Affairs, and Regulatory Affairs to ensure real-world customer insights shape clinical endpoints and site-of-care logistics.
Cultivate advisory relationships with key opinion leaders (KOLs), disease-specific medical societies, and patient advocacy groups in rheumatology, neurology, and dermatology.
Oversee selection, onboarding, and performance of therapeutic Agencies of Record (AoRs), managing a scaling commercial budget focused on multi-channel disease-state awareness.